Company News: Novo Nordisk, MedPage Today and American Academy of Family Physicians

Share this article:
The FDA approved Novo Nordisk's Victoza (liraglutide) for Type 2 diabetes, potentially setting the stage for a future shootout between rival long-acting drugs. Novo Nordisk said it plans to launch Victoza, a once-weekly drug, in four to six weeks. Meanwhile, Amylin and Eli Lilly have applied for approval of their own once-weekly Type 2 diabetes drug, Byetta LAR. It's long-acting version of Byetta (exanatide), which the two co-market. In a note to investor's today, Barclays Capital analyst Jim Birchenough wrote: “We believe approval of the first long acting GLP-1 drug bodes well for [Amylin's] once-weekly exenatide LAR and suggests a pragmatic approach by FDA to class related safety issues heading into [Amylin's March 5th PDUFA.” Birchenough increased Amylin's price target to $24 following approval of Victoza, which has a boxed warning for pancreatitis and thyroid cancer.

Online news and CME outfit MedPage Today received approval from the American Academy of Family Physicians (AAFP) to offer AAFP Elective credit for its news-based CME activities. Each MedPage Today article is approved for .25 Elective credits.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.